Ripple (XRP) has been relatively strong, climbing towards $0.70, with a cryptocurrency rally. XRP seems ready to ascend, but ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide. Weekly ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on LLY: Eli Lilly call volume above normal and directionally bullish Eli Lilly announces results from Phase 3 SURMOUNT-1 three-year study ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

Results from the Phase III SURMOUNT-1 trial show strong benefit in using the dual GLP-1/GIP agonist to lessen diabetes risk ...